An observational study in HNSCC, Oral Cavity Cancer and Oropharynx Cancer, sponsored by University Hospital Freiburg. Recruiting at 18 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by University Hospital Freiburg · Observational
Among 116 studies in Squamous Cell Carcinoma of Head and Neck with a site in Germany — 34 open to participants now, 50 under way, 14 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Germany.
Among the 116 studies in Squamous Cell Carcinoma of Head and Neck with a site in Germany, this one is the 3rd largest by planned enrollment of the 12 observational ones, is one of 16 that started in 2021, is one of 12 observational ones, reaches primary completion later than 14 of the 49 other live ones, and was the 80th registered.
2,018 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 100 across 236 observational studies indexed under Squamous Cell Carcinoma of Head and Neck.
Browse Squamous Cell Carcinoma of Head and Neck studies →34 of the 116 studies in Squamous Cell Carcinoma of Head and Neck with a site in Germany are open now, in 12 countries. Each count lists the studies.
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →116 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 16 started in 2021.
Median enrollment 178 across the 104 interventional studies, 331 across the 12 observational. Of the 61 that completed or were terminated, 25 (41%) have results posted.
74 of 116 have an industry lead sponsor. The 10 most frequent:
University Hospital Freiburg is the lead sponsor of 94 studies on the registry; 18 are open to participants now.
University Hospital Freiburg has 1 study filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
10 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT05337631University Hospital FreiburgSpecial Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy | 2026-12-31 |
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
| NCT06367257University of Erlangen-Nürnberg Medical SchoolApp-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy | 2027-04-30 |
Among the 116 studies in Squamous Cell Carcinoma of Head and Neck with a site in Germany, from their registry updates:
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.
Elderly (≥65 years) head-and-neck squamous cell carcinoma (HNSCC) patients undergoing definitive (chemo)radiotherapy since 2005 at a tertiary cancer center will be included and analyzed in terms of overall survival and the potential benefit of concomitant chemotherapy administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall survival (OS)
Time from radiotherapy start until death from any cause
Time frame: Up to 5 years
Progression-free survival (PFS)
Time from radiotherapy start until death from any cause, local progression, locoregional progression or distant progression (whichever occurs first)
Time frame: Up to 5 years
Patterns of chemotherapy administration
Type of concomitant chemotherapy
Time frame: during radiotherapy
Cumulative cisplatin dose
Dose of concomitant cisplatin in mg/m2 body surface area
Time frame: during radiotherapy
Radiotherapy compliance
Radiotherapy completion rate
Time frame: during treatment
Chemotherapy compliance
Chemotherapy completion rate
Time frame: during treatment
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
Started Jun 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Squamous Cell Carcinoma of Head and Neck →
University Hospital Freiburg